Skip to Content
MilliporeSigma
All Photos(1)

Documents

Y0001587

Atomoxetine for impurity A identification

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

(R)-Tomoxetine hydrochloride, (R)-N-Methyl-γ-(2-methyl­phenoxy)benzenepropanamine hydrochloride, Atomoxetine hydrochloride

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C17H21NO · HCl
CAS Number:
82248-59-7
Molecular Weight:
291.82
MDL number:
MFCD06410992
UNSPSC Code:
41116107
PubChem Substance ID:
329831497
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

atomoxetine

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

CNCC[C@@H](OC1=CC=CC=C1C)C2=CC=CC=C2.[H]Cl

InChI

1S/C17H21NO.ClH/c1-14-8-6-7-11-16(14)19-17(12-13-18-2)15-9-4-3-5-10-15;/h3-11,17-18H,12-13H2,1-2H3;1H/t17-;/m1./s1

InChI key

LUCXVPAZUDVVBT-UNTBIKODSA-N

Gene Information

human ... SLC6A2(6530)

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Atomoxetine for impurity A identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Norepinephrine uptake blocker.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

Y0001589

Atomoxetine impurity D, European Pharmacopoeia (EP) Reference Standard

Y0001588

Atomoxetine impurity B, European Pharmacopoeia (EP) Reference Standard

Y0001586

Atomoxetine hydrochloride, European Pharmacopoeia (EP) Reference Standard

1044469

Atomoxetine hydrochloride, United States Pharmacopeia (USP) Reference Standard

1044913

Atomoxetine S-isomer, United States Pharmacopeia (USP) Reference Standard

1044488

Atomoxetine Related Compound B, United States Pharmacopeia (USP) Reference Standard

1044491

Atomoxetine Related Compound C, United States Pharmacopeia (USP) Reference Standard

PHR1679

Atomoxetine Hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Dylan Chou et al.
Experimental neurology, 255, 19-29 (2014-03-04)
Fear conditioning in animals has been used extensively to model clinical anxiety disorders. While individual animals exhibit marked differences in their propensity to undergo fear conditioning, the physiologically relevant mediators have not yet been fully characterized. Here, we demonstrate that
Atomoxetine-induced wake-time teeth clenching and sleep bruxism in a child patient.
Kayhan Bahali et al.
European child & adolescent psychiatry, 23(12), 1233-1235 (2014-08-28)
Angie A Kehagia et al.
Brain : a journal of neurology, 137(Pt 7), 1986-1997 (2014-06-05)
Noradrenergic dysfunction may play a significant role in cognition in Parkinson's disease due to the early degeneration of the locus coeruleus. Converging evidence from patient and animal studies points to the role of noradrenaline in dopaminergically insensitive aspects of the
Atomoxetine-induced mydriasis in a child patient.
Kayhan Bahali et al.
European child & adolescent psychiatry, 23(12), 1231-1232 (2013-11-12)
Claudia E Ramirez et al.
Hypertension (Dallas, Tex. : 1979), 64(6), 1235-1240 (2014-09-04)
The clinical presentation of autonomic failure is orthostatic hypotension. Severely affected patients require pharmacological treatment to prevent presyncopal symptoms or frank syncope. We previously reported in a proof of concept study that pediatric doses of the norepinephrine transporter blockade, atomoxetine
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service